{"id":71745,"date":"2023-06-25T21:02:39","date_gmt":"2023-06-26T01:02:39","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745"},"modified":"2023-06-25T21:02:39","modified_gmt":"2023-06-26T01:02:39","slug":"ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745","title":{"rendered":"Ozempic-Wegovy pill may be on the way: Trial shows promising results for new weight loss tablet"},"content":{"rendered":"
\n

Ozempic and Wegovy \u2014 both injectable forms of semaglutide \u2014 have become synonymous with weight loss<\/u><\/a> in recent months and years. Now a new drug is on the horizon that would offer the same medication in an oral (pill) format.<\/p>\n

Created by Novo Nordisk, the same company that makes Ozempic<\/a> and Wegovy, the new drug just completed its Phase 3 clinical trials. The results were announced on Sunday at the American Diabetes Association (ADA) Scientific Session in Los Angeles, California.<\/p>\n

The oral medication, which is indicated for type 2 diabetes<\/u><\/a> or weight loss for patients with obesity, would provide an alternative to people who are not open to getting injections.<\/p>\n

WEIGHT LOSS MEDICATIONS OZEMPIC AND WEGOVY: WHAT TO KNOW BEFORE YOU STOP TAKING THEM<\/u><\/strong><\/a><\/p>\n

“The opportunity to have a tablet that can offer the effectiveness of weight loss for people with diabetes is really exciting,” Dr. Robert Gabbay, Boston-based<\/u><\/a> chief scientific and medical officer for the ADA, told Fox News Digital during a phone interview from the scientific session.\u00a0<\/p>\n

“It opens up this type of therapy to many more people that could potentially benefit.”<\/p>\n

Ozempic is marketed for people with type 2 diabetes, while Wegovy is indicated for weight loss. Both medications are semaglutides, just with different dosages.\u00a0<\/p>\n

“Our focus has been primarily on people with diabetes<\/a>, but it turns out that the vast majority of people with type 2 diabetes also have obesity,” Gabbay explained.\u00a0<\/p>\n

“So having a medication that can address a central issue for people with diabetes is really important \u2014 especially for those who are somewhat resistant to or concerned about doing an injection.”<\/p>\n

DOCTORS URGE CAUTION ON DIABETES DRUGS FOR WEIGHT LOSS AFTER STUDY HIGHLIGHTS SIDE EFFECTS<\/u><\/strong><\/a><\/p>\n

The double-blind, randomized, Phase 3 trial followed 667 people who were randomly assigned to either 50 milligrams of the drug or a placebo, explained the lead study author, Dr. Filip Knop, professor at Gentofte Hospital at the University of Copenhagen.<\/p>\n

The participants took the semaglutide once daily for a 68-week period and were monitored for both safety and effectiveness.<\/p>\n

“It’s important to emphasize that the participants were people who had obesity<\/u><\/a> but did not have type 2 diabetes,” Knop told Fox News Digital in a phone interview.\u00a0<\/p>\n

“They could have [had] pre-diabetes, but they were not allowed to be enrolled in the trial if they had type 2 diabetes.”<\/p>\n

For the 86% of participants who remained on the drug throughout the trial, they achieved an average body weight loss of 17.4% compared to just 1.8% for those on the placebo, explained Knop, who has been involved in diabetes and metabolic research since 1999.<\/p>\n

The average amount lost by the patients was 44 pounds.<\/p>\n

In addition to helping with weight loss, the semaglutide medication can also help to reduce cardiovascular disease in people with diabetes, Gabbay noted.<\/p>\n

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER<\/u><\/strong><\/a>\u00a0<\/p>\n

“For those people who are at high risk or [who] already have cardiovascular disease<\/u><\/a>, the parent drug has been shown to reduce mortality, and there\u2019s no reason to expect that this wouldn’t be the case with the oral version,” he told Fox News Digital.<\/p>\n

Common side effects during the trial were gastrointestinal in nature \u2014 such as nausea, vomiting, constipation and diarrhea \u2014 similar to what has been reported for Ozempic and Wegovy.<\/p>\n

Some less common side effects reported during the first 20 weeks of the trial were short-term changes in skin sensation, such as hypersensitivity or paraesthesia (tingling or prickling), Knop said.<\/p>\n

Following the successful results of the Phase 3 trial, the drugmakers will look to start the process of applying for FDA approval.<\/p>\n

“We’re pleased to see that there are new options for people with diabetes and obesity,” Gabbay said.\u00a0<\/p>\n

“Having something that is orally available should increase the number of people who can benefit from these kinds of treatments.”<\/p>\n<\/div>\n

Source – https:\/\/www.foxnews.com\/health\/ozempic-wegovy-pill-trial-shows-promising-results-new-weight-loss-tablet <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Ozempic and Wegovy \u2014 both injectable forms of semaglutide \u2014 have become synonymous with weight loss in recent months and years. Now a new drug […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[16563],"tags":[],"stock_ticker":[],"class_list":["post-71745","post","type-post","status-publish","format-standard","hentry","category-market-news","entry"],"acf":[],"yoast_head":"\nOzempic-Wegovy pill may be on the way: Trial shows promising results for new weight loss tablet - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ozempic-Wegovy pill may be on the way: Trial shows promising results for new weight loss tablet - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Ozempic and Wegovy \u2014 both injectable forms of semaglutide \u2014 have become synonymous with weight loss in recent months and years. Now a new drug […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-26T01:02:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2021\/06\/businessman-showing-business-evolution1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"715\" \/>\n\t<meta property=\"og:image:height\" content=\"423\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/6e00efa2abc413bdc0bca51a90c54d36\"},\"headline\":\"Ozempic-Wegovy pill may be on the way: Trial shows promising results for new weight loss tablet\",\"datePublished\":\"2023-06-26T01:02:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745\"},\"wordCount\":643,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"articleSection\":[\"Market News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745\",\"name\":\"Ozempic-Wegovy pill may be on the way: Trial shows promising results for new weight loss tablet - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"datePublished\":\"2023-06-26T01:02:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ozempic-Wegovy pill may be on the way: Trial shows promising results for new weight loss tablet\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/6e00efa2abc413bdc0bca51a90c54d36\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/09\/360_F_336393115_5gCUfwn76x3MJaCJMYDKLoRebkC8QyrL-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/09\/360_F_336393115_5gCUfwn76x3MJaCJMYDKLoRebkC8QyrL-300x300.jpg\",\"caption\":\"admin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/admin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ozempic-Wegovy pill may be on the way: Trial shows promising results for new weight loss tablet - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745","og_locale":"en_US","og_type":"article","og_title":"Ozempic-Wegovy pill may be on the way: Trial shows promising results for new weight loss tablet - Wall Street PR","og_description":"Ozempic and Wegovy \u2014 both injectable forms of semaglutide \u2014 have become synonymous with weight loss in recent months and years. Now a new drug […]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2023-06-26T01:02:39+00:00","og_image":[{"width":715,"height":423,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2021\/06\/businessman-showing-business-evolution1.jpg","type":"image\/jpeg"}],"author":"admin","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745"},"author":{"name":"admin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/6e00efa2abc413bdc0bca51a90c54d36"},"headline":"Ozempic-Wegovy pill may be on the way: Trial shows promising results for new weight loss tablet","datePublished":"2023-06-26T01:02:39+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745"},"wordCount":643,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"articleSection":["Market News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745","url":"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745","name":"Ozempic-Wegovy pill may be on the way: Trial shows promising results for new weight loss tablet - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"datePublished":"2023-06-26T01:02:39+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ozempic-wegovy-pill-may-be-on-the-way-trial-shows-promising-results-for-new-weight-loss-tablet-71745#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Ozempic-Wegovy pill may be on the way: Trial shows promising results for new weight loss tablet"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/6e00efa2abc413bdc0bca51a90c54d36","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/09\/360_F_336393115_5gCUfwn76x3MJaCJMYDKLoRebkC8QyrL-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/09\/360_F_336393115_5gCUfwn76x3MJaCJMYDKLoRebkC8QyrL-300x300.jpg","caption":"admin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/admin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/71745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=71745"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/71745\/revisions"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=71745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=71745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=71745"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=71745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}